Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Indivior Pharmaceuticals merges with Supernus

PUBLIC · SUPNAug 12, 2026•about 3 hours ago

Acquiring Company

Supernus Pharmaceuticals

Acquired Company

Indivior Pharmaceuticals

RockvilleBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnologyHealth CareMedicalPharmaceutical

Description

Indivior Pharmaceuticals has agreed to merge with Supernus Pharmaceuticals, creating a new combined entity named Supernus, Inc. The merger aims to enhance governance and operational efficiency while introducing new leadership from both companies. This strategic alliance is set to improve the product offerings and market reach in the specialty pharmaceutical sector.

Company Information

Company

Supernus Pharmaceuticals

Location

Rockville, Maryland, United States

About

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company has a significant experience in CNS and has successfully introduced more than eight widely recognized products in this therapeutic category. Their recent advancement includes ONAPGO, a subcutaneous apomorphine infusion device for treating motor fluctuations associated with Parkinson’s disease. Supernus is committed to developing novel alternatives for managing neurological conditions.

Don't miss Supernus Pharmaceuticals's next move

Get an email the moment Supernus Pharmaceuticals makes an acquisition, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Supernus Pharmaceuticals's next move

Learn about Strategic plan

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Indivior Pharmaceuticals?

Indivior Pharmaceuticals was acquired by Supernus Pharmaceuticals, based in Rockville. The deal was reported on August 12, 2026. Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Supernus Pharmaceuticals is publicly traded (SUPN) and operates in Biotechnology.

When did Supernus Pharmaceuticals acquire Indivior Pharmaceuticals?

Supernus Pharmaceuticals's acquisition of Indivior Pharmaceuticals was reported on August 12, 2026. Indivior Pharmaceuticals has agreed to merge with Supernus Pharmaceuticals, creating a new combined entity named Supernus, Inc. The merger aims to enhance governance and operational efficiency while introducing new leadership from both companies. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Indivior Pharmaceuticals do?

Indivior Pharmaceuticals, Inc. specializes in the treatment of addiction and is engaged in developing medicines to help individuals with substance use disorders. It is publicly traded (INDV), operating in Biotechnology.